Catalyst
Slingshot members are tracking this event:
Janssen (JNJ) Initiates Phase 2b Study Evaluating Simeprevir/Odalasvir/JNJ-4178 in Chronic Hepatitis C Virus Infection Genotypes 1,2,4,5 and 6 Without Cirrhosis
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 28, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Phase 2b, Simeprevir, Odalasvir, Jnj-4178, Chronic Hepatitis C Virus Infection, Genotype 2, Genotype 1, Genotype 1 Or 4, Genotype 5, Genotype 6, Cirrhosis
